Pharmerica Corporation Rating Increased to Outperform at RBC Capital (PMC)
Shares of Pharmerica Corporation traded down 2.19% during mid-day trading on Thursday, hitting $11.60. Pharmerica Corporation has a 52 week low of $10.43 and a 52 week high of $16.45. The company has a market cap of $342.1 million and a P/E ratio of 13.65.
The company last announced its quarterly results on Wednesday, May 2nd. It reported $0.30 earnings per share (EPS) for the previous quarter, beating the Thomson Reuters consensus estimate of $0.27 EPS by $0.03. The company’s quarterly revenue was down 6.8% on a year-over-year basis. Analysts expect that Pharmerica Corporation will post $0.30 EPS next quarter.
Other equities research analysts have also recently issued reports about the stock. Analysts at UBS AG (NYSE: UBS) cut their price target on shares of Pharmerica Corporation from $15.00 to $13.00 in a research note to investors on Wednesday, April 25th. They now have a “neutral” rating on the stock. Analysts at Zacks upgraded shares of Pharmerica Corporation from a “neutral” rating to an “outperform” rating in a research note to investors on Saturday, February 18th.
PharMerica Corporation is an institutional pharmacy services company that services healthcare facilities and provides management pharmacy services to hospitals.